Status:
COMPLETED
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
Lead Sponsor:
BioSante Pharmaceuticals
Conditions:
Hypoactive Sexual Desire Disorder
Eligibility:
FEMALE
30-66 years
Phase:
PHASE3
Brief Summary
The objective of this study is to evaluate the persistence of benefit of LibiGel (testosterone gel) 300 mcg/day compared to placebo gel in a 12 week post-treatment period of Hypoactive Sexual Desire D...
Eligibility Criteria
Inclusion
- must have completed a minimum of 22 weeks of the 24-week TESTW006 or TESTW008 clinical trial
Exclusion
- Any condition (including a change in sexual or relationship history) that would make the subject unsuitable for participation in the trial in the opinion of the Investigator
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
626 Patients enrolled
Trial Details
Trial ID
NCT01235754
Start Date
October 1 2010
End Date
January 1 2012
Last Update
January 10 2013
Active Locations (102)
Enter a location and click search to find clinical trials sorted by distance.
1
BioSante Site #095
Hoover, Alabama, United States, 35216
2
BioSante Site #014
Huntsville, Alabama, United States, 35801
3
BioSante Site #146
Mobile, Alabama, United States, 36608
4
BioSante Site #171
Chandler, Arizona, United States, 85224